Virtu Financial LLC Has $797,000 Stock Holdings in Ocular Therapeutix, Inc. $OCUL

Virtu Financial LLC boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 470.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,627 shares of the biopharmaceutical company’s stock after purchasing an additional 54,117 shares during the quarter. Virtu Financial LLC’s holdings in Ocular Therapeutix were worth $797,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC raised its position in shares of Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,242 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Ocular Therapeutix by 1.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock worth $674,000 after buying an additional 1,314 shares during the period. Trust Co. of Vermont grew its stake in Ocular Therapeutix by 24.3% in the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,750 shares during the last quarter. Rafferty Asset Management LLC grew its stake in Ocular Therapeutix by 21.2% in the 2nd quarter. Rafferty Asset Management LLC now owns 13,413 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 2,343 shares during the last quarter. Finally, Creative Planning raised its holdings in Ocular Therapeutix by 14.6% in the 3rd quarter. Creative Planning now owns 24,535 shares of the biopharmaceutical company’s stock valued at $287,000 after acquiring an additional 3,125 shares during the period. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on OCUL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Tuesday, April 21st. Needham & Company LLC reiterated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. William Blair reissued an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Robert W. Baird boosted their price target on Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $24.89.

Ocular Therapeutix Stock Performance

NASDAQ OCUL opened at $9.97 on Tuesday. The firm has a 50-day moving average price of $9.00 and a two-hundred day moving average price of $9.89. Ocular Therapeutix, Inc. has a 12-month low of $6.23 and a 12-month high of $16.44. The company has a market capitalization of $2.18 billion, a P/E ratio of -6.83 and a beta of 0.89. The company has a quick ratio of 14.73, a current ratio of 14.81 and a debt-to-equity ratio of 0.12.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,156 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total value of $173,479.20. Following the completion of the sale, the insider directly owned 2,597,170 shares in the company, valued at approximately $21,296,794. The trade was a 0.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 28,999 shares of company stock valued at $237,792 in the last three months. 3.10% of the stock is currently owned by insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.